On January 19, 2026, the Chengdu Hi-Tech Medical Association successfully hosted the "SmartLink Healthcare" roadshow for enterprises in the pharmaceutical and health industry. The association has consistently been committed to driving innovative development in the regional pharmaceutical and health sector. Grounded in the "Minshan Torch Program," it is dedicated to building an open, collaborative resource integration platform and a "talent reservoir." This initiative aims to pool projects, capital, technology, and talent, providing fertile ground for the growth of early-stage innovative enterprises.

Through its secondary subsidiary, the Chengdu Hi-Tech Medical Association, in collaboration with Shenzhen Qianhai Ruilin, jointly established a three-tier platform company adopting a dual-general partner (dual-GP) structure. Under this cooperation framework, Qianhai Ruilin will serve as the fund manager, while the Association leverages its strengths as a resource coordination and integration platform. Together, they have jointly established a pharmaceutical and healthcare industry fund, steadfastly adhering to the core strategy of "investing early, investing small, and investing in high technology." The fund will focus on deploying resources in high-growth-potential early-stage technology enterprises.

The company is dedicated to the research, development, and application of full-color bionic light technology, aiming to optimize human living environments through healthy light sources. Its monocrystalline full-color bionic light CSP flip-chip has achieved intensity levels in the 640–700nm red light band that meet the standards of sunlight in the same wavelength range, fully demonstrating the potential to achieve therapeutic effects with healthy light. Its technological capabilities have surpassed those of leading global companies in this field. In the future, this technology is expected to find broad applications in areas such as vision health, general wellness, national defense, electronics, and agriculture.

The company is a technology firm specializing in eye health management, with core businesses encompassing software development, artificial intelligence applications, and medical device sales. It is committed to both technological innovation and the translation of research outcomes into practical applications. Its independently developed core products have already addressed several technological gaps in China's ophthalmic field and are protected by multiple patents. Moving forward, the company will continue to deepen its focus on building internet-based ophthalmic operation systems and actively invest in the research, development, and innovation of a new generation of AI-powered ophthalmic products.

This company is a high-tech enterprise specializing in the research and development, production, sales, and technical services of high-end functional foods. Grounded in the holistic principles of traditional Chinese medicine and modern molecular genetics, it focuses on molecular nutrition and functional foods by precisely targeting cellular signaling pathways and modulating gene expression, aiming to prevent and ameliorate diseases at their root. To date, the company has accumulated over 20 domestic and international patents. Moving forward, it plans to adopt an innovative model in the fields of molecular nutrition research and community nutrition services to build a globally leading ecosystem for community health services.

This company is a high-tech enterprise specializing in biotechnology. Its core product, as the world's first graphene medical device, redefines the technological core of non-pharmacological therapies based on precision energy programming technology utilizing same-frequency resonance. It establishes the foundational technical logic and irreplicable systemic advantages in this field, creating a significant technological barrier. In the future, the company plans to further deepen the research and development of its core algorithms, accelerate efforts to obtain global market access certifications such as FDA and CE for its products, expand production capacity, and enhance the layout of its production chain, supply chain, and marketing system.

      The company focuses on cloud computing, big data, and artificial intelligence in the healthcare sector. Leveraging its expertise in cloud computing, big data, and AI, it delves into the integration and innovative application of technology within medical scenarios. It has established a three-tier core competency framework comprising a medical-grade cloud platform, a leading domestic large-scale model for the healthcare industry, and medical AI agents. In the future, the company will continue to strengthen product and technology research and development, deepen the iteration of digital doctor systems, expand the application of medical AI agents, increase investment in computing infrastructure, refine its AI platform strategy, and continuously enhance its market influence through a dual-drive approach of brand and product development.

     The project focuses on the application of brain-computer interface technology, aiming to establish a safe, non-invasive, and deeply integrated non-pharmacological intervention model for patients with conditions such as Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Major Depressive Disorder (MDD), and Alzheimer’s Disease (AD). Leveraging AI technology, the project develops a personalized brain health digital therapy featuring a "cognitive-emotional dual closed-loop" system tailored for ADHD, AD, ASD, and MDD. It also innovatively proposes a strategy of "adaptive threshold optimization driven by goal achievement rates combined with emotion perception." Supported by cloud-based services and close collaboration with university research teams, the project possesses a solid research foundation and promising development prospects.

     This event gathered multiple outstanding enterprises, aiming to build an efficient bridge for resource alignment. It is designed to help investors gain a concentrated and systematic understanding of the technological strengths and business models of innovative companies, thereby seizing potential collaboration opportunities.

      This roadshow marks the beginning of a series of events. Moving forward, the Chengdu Hi-Tech Medical Association will continue to organize specialized sessions focused on investment and financing, strategic consulting, and specialized training, among other resource-linking activities. These initiatives aim to provide all parties with a sustained and in-depth communication platform, jointly injecting new momentum into the innovative development of the pharmaceutical and health industry!